Free Trial

Sangamo Therapeutics (SGMO) Competitors

Sangamo Therapeutics logo
$0.66 +0.02 (+2.40%)
Closing price 10/22/2025 04:00 PM Eastern
Extended Trading
$0.66 -0.01 (-0.76%)
As of 10/22/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SGMO vs. GERN, MYGN, VSTM, LXRX, EBS, RIGL, XOMA, VNDA, IRWD, and CDXS

Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Geron (GERN), Myriad Genetics (MYGN), Verastem (VSTM), Lexicon Pharmaceuticals (LXRX), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), Ironwood Pharmaceuticals (IRWD), and Codexis (CDXS). These companies are all part of the "biotechnology" industry.

Sangamo Therapeutics vs. Its Competitors

Geron (NASDAQ:GERN) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Geron has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.

Geron presently has a consensus price target of $3.79, indicating a potential upside of 205.30%. Sangamo Therapeutics has a consensus price target of $4.50, indicating a potential upside of 581.82%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than Geron.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Geron
2 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13
Sangamo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

Sangamo Therapeutics has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Geron$76.99M10.28-$174.57M-$0.13-9.54
Sangamo Therapeutics$57.80M3.45-$97.94M-$0.29-2.28

Geron has a net margin of -53.52% compared to Sangamo Therapeutics' net margin of -77.48%. Geron's return on equity of -31.37% beat Sangamo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Geron-53.52% -31.37% -16.01%
Sangamo Therapeutics -77.48%-293.05%-63.85%

73.7% of Geron shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 7.4% of Geron shares are owned by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Geron had 3 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 4 mentions for Geron and 1 mentions for Sangamo Therapeutics. Geron's average media sentiment score of 0.71 beat Sangamo Therapeutics' score of 0.59 indicating that Geron is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Geron
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Sangamo Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Geron beats Sangamo Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Sangamo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SGMO vs. The Competition

MetricSangamo TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$194.45M$3.47B$6.17B$10.67B
Dividend YieldN/A2.24%5.72%4.86%
P/E Ratio-2.2822.9129.0927.13
Price / Sales3.45463.56574.60126.20
Price / CashN/A45.5937.1261.42
Price / Book6.0010.2912.216.43
Net Income-$97.94M-$52.53M$3.33B$276.63M
7 Day Performance2.34%-0.60%-0.78%-0.77%
1 Month Performance25.17%10.30%5.29%0.68%
1 Year Performance-57.14%13.51%68.54%32.03%

Sangamo Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SGMO
Sangamo Therapeutics
1.9986 of 5 stars
$0.66
+2.4%
$4.50
+581.8%
-45.5%$194.45M$57.80M-2.28480News Coverage
GERN
Geron
2.9661 of 5 stars
$1.27
-3.1%
$3.79
+198.1%
-69.1%$810.29M$76.99M-9.7770
MYGN
Myriad Genetics
3.7145 of 5 stars
$7.84
+4.5%
$12.45
+58.9%
-65.3%$729.43M$837.60M-1.832,700
VSTM
Verastem
3.1893 of 5 stars
$9.29
+8.4%
$13.29
+43.0%
+129.8%$571.71M$10K-2.8350Analyst Upgrade
Analyst Revision
LXRX
Lexicon Pharmaceuticals
2.3626 of 5 stars
$1.44
-3.4%
$3.23
+124.0%
-28.4%$523.30M$31.08M-4.36140
EBS
Emergent Biosolutions
4.2683 of 5 stars
$9.31
+2.7%
$13.50
+45.0%
+2.4%$496.80M$1.04B3.802,420Upcoming Earnings
RIGL
Rigel Pharmaceuticals
3.546 of 5 stars
$26.83
-4.8%
$38.20
+42.4%
+106.5%$481.25M$267.92M4.96160
XOMA
XOMA Royalty
3.9109 of 5 stars
$36.17
-0.7%
$69.50
+92.1%
+18.2%$437.30M$28.49M-23.3410Analyst Downgrade
VNDA
Vanda Pharmaceuticals
4.0894 of 5 stars
$5.23
-1.5%
$16.50
+215.5%
+12.9%$309.04M$198.77M-4.63290
IRWD
Ironwood Pharmaceuticals
4.5034 of 5 stars
$1.48
-6.6%
$4.94
+233.8%
-61.5%$240.40M$308.52M-29.59220News Coverage
CDXS
Codexis
3.643 of 5 stars
$2.50
-3.5%
$11.00
+340.0%
-22.4%$225.67M$57.16M-3.01250Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:SGMO) was last updated on 10/23/2025 by MarketBeat.com Staff
From Our Partners